Literature DB >> 18215355

Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-kappaB pathway.

Yang Xue1, Ying Wang, De-chun Feng, Bao-guo Xiao, Ling-yun Xu.   

Abstract

AIM: Microglial activation has been implicated in many neurological diseases. In this study, we examined the effects of tetrandrine (TET), a major pharmacologically-active compound of Chinese herb Stephania tetrandra S Moore on microglial activation.
METHODS: The microglia pretreated with or without TET were activated by lipopolysaccharide (LPS) in vitro. Nitric oxide (NO) release, superoxide anion (O2-) generation, as well as TNF-alpha and interleukin-6 (IL-6) production by microglia were measured afterwards. Electrophoretic mobility shift assay was performed to determine whether NF-kappaB activity in microglia was affected by TET treatment.
RESULTS: We found that TET inhibited the LPS-induced activation of microglia by decreasing the production of NO and O2-, consequently affecting the release of TNF-alphaand IL-6 in LPS-induced microglial activation. Such suppressive effect was accompanied by inhibiting transcription factor NF-kappaB activation.
CONCLUSION: Our results suggest that TET might modulate LPS-induced microglial activation by inhibiting the NF-kappaB-mediated release of inflammatory factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215355     DOI: 10.1111/j.1745-7254.2008.00734.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  18 in total

1.  Differential roles of PKA and Epac on the production of cytokines in the endotoxin-stimulated primary cultured microglia.

Authors:  Jian Liu; Xin Zhao; Jianping Cao; Qingsheng Xue; Xiaomei Feng; Xuesheng Liu; Fujun Zhang; Buwei Yu
Journal:  J Mol Neurosci       Date:  2010-07-18       Impact factor: 3.444

2.  Mesenchymal stem cells inhibited the inflammation and oxidative stress in LPS-activated microglial cells through AMPK pathway.

Authors:  Dayong Cao; Haowen Qiao; Dejiao He; Xingping Qin; Qian Zhang; Yu Zhou
Journal:  J Neural Transm (Vienna)       Date:  2019-11-09       Impact factor: 3.575

3.  Tetrandrine Alleviates Nociception in a Rat Model of Migraine via Suppressing S100B and p-ERK Activation in Satellite Glial Cells of the Trigeminal Ganglia.

Authors:  Guangcheng Qin; Bei Gui; Jingmei Xie; Lixue Chen; Lianlian Chen; Zhiwei Cui; Jiying Zhou; Ge Tan
Journal:  J Mol Neurosci       Date:  2017-11-16       Impact factor: 3.444

4.  siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia.

Authors:  Hao Cheng; Zhifang Wu; Xiaoyun He; Qingzhen Liu; Hongbin Jia; Yan Di; Qing Ji
Journal:  Exp Ther Med       Date:  2016-08-04       Impact factor: 2.447

5.  Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs-IkappaBalpha-NF-kappaB signaling pathway.

Authors:  Shu-Ting Lin; Ying Wang; Yang Xue; De-Chun Feng; Yan Xu; Ling-Yun Xu
Journal:  Mol Cell Biochem       Date:  2008-05-23       Impact factor: 3.396

6.  ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.

Authors:  Xin-ming Qi; Ling-ling Miao; Yan Cai; Li-kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2013-07-29       Impact factor: 6.150

7.  Cloning of crystallin from orange-spotted grouper and characterization of its activity as potential protective agent.

Authors:  Young-Mao Chen; Cham-En Kuo; Chun-Mao Lin; Pei-Shiuan Shie; Tzong-Yueh Chen
Journal:  Results Immunol       Date:  2011-09-09

8.  Tetrandrine attenuated cerebral ischemia/reperfusion injury and induced differential proteomic changes in a MCAO mice model using 2-D DIGE.

Authors:  Lin Ruan; Huan-Sen Huang; Wen-Xiang Jin; Hai-Ming Chen; Xiong-Juan Li; Qing-Juan Gong
Journal:  Neurochem Res       Date:  2013-06-19       Impact factor: 3.996

9.  Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-κB and ERK signaling pathways in BV2 cells.

Authors:  Yalong Dang; Yongsheng Xu; Wentao Wu; Weiyi Li; Yanran Sun; Jing Yang; Yu Zhu; Chun Zhang
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

10.  Combination Nanotherapeutics for Dry Eye Disease Treatment in a Rabbit Model.

Authors:  Liandi Huang; Huanhuan Gao; Zhigang Wang; Yixin Zhong; Lan Hao; Zhiyu Du
Journal:  Int J Nanomedicine       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.